- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05543681
Ensayo IGC-AD1 sobre la agitación en la demencia debida a la enfermedad de Alzheimer (CALMA)
Un ensayo de fase 2, multicéntrico, doble ciego, aleatorizado, controlado con placebo, de la seguridad y eficacia de IGC-AD1 sobre la agitación en participantes con demencia debido a la enfermedad de Alzheimer
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
CALMA is a multi-center, double-blind, randomized, placebo-controlled clinical trial. The study targets participants aged 60 and older with mild to severe Alzheimer's dementia who have exhibited clinically significant agitation for at least two weeks prior to enrollment. Agitation caused by other conditions or transient symptoms must be ruled out. Eligibility is determined by a baseline Neuropsychiatric Inventory (NPI-12), Agitation subscale score of ≥4 and the International Psychogeriatric Association (IPA) criteria for agitation.
The investigational medication is an oral solution containing two active ingredients: delta-9 tetrahydrocannabinol (THC) and melatonin. The treatment is administered for 42 days, followed by a two-day taper period at the end of the study.
Safety oversight includes daily calls on days 2, 3, and 4, transitioning to calls every third day thereafter. These calls will review study partners logbook entries, changes in concomitant medications, and adverse events.
The primary objective of the study is to evaluate the efficacy of IGC-AD1 on agitation, measured by changes in the Cohen-Mansfield Agitation Inventory (CMAI) scores from baseline to the End of treatment (EOT). The secondary objective is to assess efficacy by examining CMAI score changes from baseline to week two. Additionally, exploratory objectives are outlined in separate documentation.
Blood samples will be collected during the trial for sparse pharmacokinetic (PK) analysis, blood-based CNS biomarker, and genotyping.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
British Columbia
-
Victoria, British Columbia, Canadá, V8R 1J8
- Island Health Authorities
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8M 1W9
- Hamilton Health Sciences , Mcmaster University
-
Toronto, Ontario, Canadá, ON M6A 2E1
- Baycrest Academy for Research and Education , University of Toronto
-
-
Quebec
-
Montreal, Quebec, Canadá, H4H 1R3
- Douglas Hospital Research Center, McGill university
-
-
-
-
Florida
-
Maitland, Florida, Estados Unidos, 32751
- ClinCloud, LLC
-
Melbourne, Florida, Estados Unidos, 32940
- ClinCloud, LLC
-
Miami, Florida, Estados Unidos, 33133
- Visionary Investigators Network
-
Miami, Florida, Estados Unidos, 33137
- Miami Jewish Health
-
Miami, Florida, Estados Unidos, 33125
- Central Miami Medical Institute
-
Port Charlotte, Florida, Estados Unidos, 33952
- Neurostudies Inc.
-
Tampa, Florida, Estados Unidos, 33613
- University of South Florida Department of Psychiatry and Behavioral Neurosciences
-
-
Louisiana
-
Metairie, Louisiana, Estados Unidos, 70006
- Tandem Clinical Research GI, LLC
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21237
- MedStar Franklin Square Medical Center Neurology
-
Clinton, Maryland, Estados Unidos, 20735
- Medstar Southern Maryland Hospital Center
-
Olney, Maryland, Estados Unidos, 20832
- Medstar Montgomery Medical Center
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63128
- Tekton Research LLC
-
-
New York
-
Amherst, New York, Estados Unidos, 02459
- Dent Neurologic Institute
-
Brooklyn, New York, Estados Unidos, 11229
- Integrative Clinical Trials, LLC
-
Syracuse, New York, Estados Unidos, 13210
- Ichor Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73112
- Lynn Health Science Institute (LHSI)
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02906
- Butler Hospital, Brown University
-
-
Texas
-
Austin, Texas, Estados Unidos, 78757
- Senior Adults Specialty Research
-
Dallas, Texas, Estados Unidos, 75231
- Kerwin Medical Center
-
Dallas, Texas, Estados Unidos, 75231
- Baylor Scott and White Research Institute
-
-
Virginia
-
Richmond, Virginia, Estados Unidos, 23219
- Dominion Medical Associates, Inc.
-
-
-
-
-
Bayamón, Puerto Rico, 00961
- SCB Research Center Corp
-
Rio Piedras, Puerto Rico, 00935
- The Alliance, Medical Sciences Campus University of Puerto Rico
-
-
Bayamón
-
Bayamón, Bayamón, Puerto Rico, 00961
- Instituto Sanacoop
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
To be eligible to participate in this study, the participant must meet all the following criteria:
Inclusion Criteria
-
Participant and/or Caregiver must provide a signed and dated ICF prior to any study procedures.
-
Must have a Caregiver who is able and willing to comply with all required study procedures.
-
The Caregiver must be known to the Participant and must be able to use electronic devices such as a cell phone, video conference over a laptop or cell phone, weighing scale, and be able to learn to take blood pressure, among others.
-
Based on local practice, Participants that cannot consent may have Caregiver's consent provided the Caregiver has among others a) Power of Attorney, b) is a spouse, or c) a sibling or d) a child or e) a close relation. The practice of accepting consent must be consistent with established practice at the site and jurisdiction.
-
Participants must consent to CYP450 and apolipoprotein E (ApoE) genotyping, and pharmacokinetics.
-
Diagnosis of AD by NIA-AA criteria
-
Clinically significant Agitation assessed by:
- NPI (Agitation) ≥ 4
- The presence of clinically significant, persistent Agitation based on the IPA definition (Appendix C) rather than those with recent onset and occasional symptoms, and
- Agitation not attributable to another psychiatric disorder, suboptimal care conditions, other underlining medical condition, or the physiological effects of a substance.
-
Negative drug screen, except for benzodiazepines if Participant has been using them in stable doses for at least 3 months before screening.
-
All medications used for behavioral symptoms should be consistent for at least 6 weeks before screening, with allowance for dose changes up to 25%.
-
Women must be of no childbearing potential (postmenopausal, defined as cessation of menses for at least 12 months, without an alternative medical cause for amenorrhea) or surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation)).
An individual who meets any of the following criteria will be excluded from participation in this study:
Exclusion Criteria
- Prior adverse reaction to cannabinoids or to any component of Study Drug (IGC-AD1 and placebo).
- Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease, which might confound assessment of safety outcomes.
- History of seizures, schizophrenia, or bipolar disorder.
- Has participated in an investigational drug or device study within 30 days prior to study start.
- Urine drug screen positive for drug use, except for benzodiazepines if Participant was using them previously and their dose had remained stable for at least six weeks before screening.
- History of Alcohol and Drug use disorder, within one year prior to enrollment.
- Hypertension: Participants with a history of uncontrolled hypertension as determined by the PI and Participants with a hypertensive crisis in the six months prior to enrollment.
- Falls: Participants with a history of recurrent falls defined as more than two falls in the six-month period prior to enrollment and a history of falls resulting in injuries or associated with a new acute illness, loss of consciousness, fever, or abnormal blood pressure (Fuller et al., 2000).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Active Comparator: IGC-AD1Active
IGC-AD1-Active, oral solution with two APIs (THC and melatonin). |
A non-sterile solution for oral administration.
Otros nombres:
|
|
Comparador de placebos: Placebo Comparator: IGC-AD1 Placebo
IGC-AD1-Placebo, oral solution similar to Active in color, taste, and texture, with excipients but without APIs. |
A non-sterile solution for oral administration similar in color and texture to the Active.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Agitation
Periodo de tiempo: Baseline to week six
|
Change in mean Cohen Mansfield Agitation Inventory (CMAI) score |
Baseline to week six
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Acute Agitation
Periodo de tiempo: Baseline to week two
|
Change in mean Cohen Mansfield Agitation Inventory (CMAI) score |
Baseline to week two
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Agitation at week four
Periodo de tiempo: Baseline to week four
|
Change in mean Cohen Mansfield Agitation Inventory (CMAI) score |
Baseline to week four
|
|
Participant overall wellbeing
Periodo de tiempo: Baseline to weeks two and six
|
Change in the Clinical Global Impression Scale (CGI) |
Baseline to weeks two and six
|
|
Participant executive functions
Periodo de tiempo: Baseline to week six
|
Change in Mini-Mental State Examination (MMSE2) score |
Baseline to week six
|
|
Depression
Periodo de tiempo: Baseline to weeks two, four, and six
|
Change in mean Cornell Scale for Depression in Dementia (CSDD) score |
Baseline to weeks two, four, and six
|
|
Neuropsychiatric symptoms
Periodo de tiempo: Baseline to weeks two, four, and six
|
Change in mean Neuropsychiatric Inventory (NPI-12) score |
Baseline to weeks two, four, and six
|
|
Participant quality of life
Periodo de tiempo: Baseline to weeks two, four and six
|
Change in mean Quality of Life in Alzheimer's Disease (QOL-AD) score |
Baseline to weeks two, four and six
|
|
Caregiver burden
Periodo de tiempo: Baseline to weeks two and six
|
Change in mean Zarit Burden Interview (ZBI) score |
Baseline to weeks two and six
|
|
Psychotropic drugs
Periodo de tiempo: Baseline to six weeks
|
Change in type and dosage of psychotropic drugs |
Baseline to six weeks
|
|
CYP2C9 polymorphisms on agitation
Periodo de tiempo: Baseline to weeks two, four and six
|
Change in mean Cohen Mansfield Agitation Inventory (CMAI) score for each type of metabolizer group (*1/*1, *1/*3, etc.) |
Baseline to weeks two, four and six
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Comportamiento motor aberrante en la demencia
- Manifestaciones neurológicas
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Desordenes mentales
- Síntomas de comportamiento
- Manifestaciones neuroconductuales
- Trastornos neurocognitivos
- Tauopatías
- Enfermedades neurodegenerativas
- Trastornos relacionados con sustancias
- Trastornos inducidos químicamente
- Estrés Psicológico
- Discinesias
- Trastornos psicomotores
- Condiciones Patológicas, Signos y Síntomas
- Comportamiento
- Signos y síntomas
- Comportamiento social
- Carga del cuidador
- Desórdenes de ansiedad
- Enfermedad de Alzheimer
- Depresión
- Abuso de marihuana
- Demencia
- Agitación psicomotora
- Agresión
- Actividad motora
- Movimiento
- Fenómenos fisiológicos musculoesqueléticos
- Fenómenos fisiológicos musculoesqueléticos y neuronales
- Ejercicio
Otros números de identificación del estudio
- IGC-AD1-P2 BIDAG
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .